coin-img-ETHETH-2.69%coin-img-BTCBTC-2.62%coin-img-SOLSOL-3.51%coin-img-XRPXRP-3.79%coin-img-UBOXUBOX+0.00%coin-img-USDCUSDC+0.02%coin-img-HYPEHYPE-6.03%coin-img-TRXTRX-1.51%coin-img-ETHETH-2.69%coin-img-BTCBTC-2.62%coin-img-SOLSOL-3.51%coin-img-XRPXRP-3.79%coin-img-UBOXUBOX+0.00%coin-img-USDCUSDC+0.02%coin-img-HYPEHYPE-6.03%coin-img-TRXTRX-1.51%coin-img-ETHETH-2.69%coin-img-BTCBTC-2.62%coin-img-SOLSOL-3.51%coin-img-XRPXRP-3.79%coin-img-UBOXUBOX+0.00%coin-img-USDCUSDC+0.02%coin-img-HYPEHYPE-6.03%coin-img-TRXTRX-1.51%coin-img-ETHETH-2.69%coin-img-BTCBTC-2.62%coin-img-SOLSOL-3.51%coin-img-XRPXRP-3.79%coin-img-UBOXUBOX+0.00%coin-img-USDCUSDC+0.02%coin-img-HYPEHYPE-6.03%coin-img-TRXTRX-1.51%
user-avatar
The Manila Times

Atea says Phase 3 CBEYOND trial hits endpoints, with BEM/RZR posting 93.9% SVR at Week 24

AI Market Summary
Atea Pharmaceuticals reported positive topline Phase 3 CBEYOND results for bemnifosbuvir/ruzasvir in chronic HCV, meeting primary and secondary endpoints with statistical noninferiority versus sofosbuvir/velpatasvir and demonstrating strong 8-week cure rates in non-cirrhotic patients. The readout reduces late-stage development uncertainty and supports a differentiated clinical profile, which can improve perceived probability of regulatory success. Broader market spillover appears limited.
Impact level
● Low
Affected assets
AVAAI/USDT-5.97%
AI Insight · AVAAI/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Atea Pharmaceuticals said its hepatitis C regimen bemnifosbuvir/ruzasvir met both the primary and secondary endpoints in the North America Phase 3 C-BEYOND trial. In the modified intent-to-treat population, the sustained virologic response rate was 93.9%, statistically noninferior to 94.8% for sofosbuvir/velpatasvir. Among patients without cirrhosis, an 8-week course of bemnifosbuvir/ruzasvir achieved a 93.5% cure rate.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Finance

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.